Azathioprine or mercaptopurine therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35565
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2024.
- Pamphlet Number
- 1079
- Available Online
- View Pamphlet
Azathioprine (Imuran®) or mercaptopurine may help you manage your over-active immune response caused by your inflammatory bowel disease (IBD). This pamphlet gives information about combination therapy in IBD, possible side effects of these medications, and what you can do to lower the chance of side effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Alternate Title
- Azathioprine or mercaptopurine therapy for IBD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2024
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (6 p.): digital, PDF file
- Subjects (MeSH)
- Immunosuppressive Agents
- Azathioprine
- Mercaptopurine
- Subjects (LCSH)
- Immunosuppressive agents
- Specialty
- Medications
- Abstract
- Azathioprine (Imuran®) or mercaptopurine may help you manage your over-active immune response caused by your inflammatory bowel disease (IBD). This pamphlet gives information about combination therapy in IBD, possible side effects of these medications, and what you can do to lower the chance of side effects.
- Notes
- Previous title: Azathioprine (Imuran) therapy
- Previous title: Azathioprine and mercaptopurine therapy
- Responsibility
- Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Pamphlet Number
- 1079
